Scarica l'app Stockscreener
89.86
1.34%
-1.22
Dopo l'orario di chiusura:
89.86
Precedente Chiudi:
$91.08
Aprire:
$91.35
Volume 24 ore:
907.20K
Relative Volume:
0.92
Capitalizzazione di mercato:
$5.15B
Reddito:
$360.35M
Utile/perdita netta:
$-149.57M
Rapporto P/E:
-30.36
EPS:
-2.96
Flusso di cassa netto:
$-81.27M
1 W Prestazione:
+6.15%
1M Prestazione:
-8.55%
6M Prestazione:
-41.34%
1 anno Prestazione:
-28.20%
Intervallo 1D:
$89.13
$92.22
Intervallo di 1 settimana:
$84.37
$92.69
Portata 52W:
$77.10
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Nome
Glaukos Corporation
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Confronta GKOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
89.86 | 5.22B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
131.75 | 225.01B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 154.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.71B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 117.85B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.26 | 45.90B | 5.69B | 1.41B | 577.90M | 6.95 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corporation Borsa (GKOS) Ultime notizie
Glaukos Highlights Innovation in Recent Investor Presentation - TipRanks
Glaukos Corporation shares rise 1.32% intraday after investor presentation in August 2024. - AInvest
RSI + MACD Show Convergence for Glaukos Corporation2025 Growth vs Value & High Accuracy Trade Alerts - 선데이타임즈
Glaukos Emphasizes Innovation in Recent Investor Presentation: A Closer Look - AInvest
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Glaukos (GKOS) - The Globe and Mail
Glaukos Announces Participation in Wells Fargo Healthcare Conference | GKOS Stock News - GuruFocus
Glaukos Announces Participation in Wells Fargo Healthcare Conference - sg.finance.yahoo.com
Midday Stock Roundup: Tilly’s Jumps 22% - Orange County Business Journal
What Glaukos (GKOS)'s Strong Q2 Results and Upgraded Guidance Mean For Shareholders - simplywall.st
Glaukos shares fall 41% after InvestingPro’s February overvaluation alert By Investing.com - Investing.com Nigeria
Glaukos (GKOS) Narrows Loss and Lifts Full-Year Outlook After Second-Quarter Results – What's Changed - simplywall.st
Glaukos Corporation (NYSE:GKOS) Q1 2025 Earnings Call Transcript - MSN
What catalysts could drive Glaukos Corporation stock higher in 2025Access high-quality stock research instantly - Jammu Links News
What is the dividend policy of Glaukos Corporation stockExceptional growth trajectory - Jammu Links News
How strong is Glaukos Corporation company’s balance sheetCapitalize on market momentum for big wins - Jammu Links News
What analysts say about Glaukos Corporation stockMaximize portfolio growth with expert advice - Jammu Links News
Is Glaukos Corporation a good long term investmentUnlock expert trading strategies for growth - Jammu Links News
What markets is MBIO expanding into Is Glaukos Corporation stock a good long term investment optionFree Trend-Following Techniques - Jammu Links News
Press Release: Glaukos Announces Second Quarter 2025 Financial Results - 富途牛牛
Glaukos Q2 Revenue Up 30%: Strong Adoption of Glaucoma Products in US and Global Expansion - AInvest
Glaukos (GKOS) Maintains Rating, Raises Price Target to $92. - AInvest
Glaukos Corporation's Q2 Earnings: Analysts Reassess Growth Prospects - AInvest
Glaukos Corporation (NYSE:GKOS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo.co
Glaukos Corporation (NYSE:GKOS) Q2 2025 Earnings Call Transcript - Insider Monkey
Glaukos (GKOS) Q2 Revenue Jumps 30% - Nasdaq
Glaukos Corp. Reports Record Growth Amid Challenges - TipRanks
Forecasting Glaukos Corporation price range with options dataOversold Recovery Opportunity Stocks Attract Buyers - metal.it
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised - Yahoo Finance
What is the risk reward ratio of investing in Glaukos Corporation stockSmart Portfolio Watchlist To Watch Now - Jammu Links News
Glaukos price target raised to $118 from $117 at BTIG - TipRanks
Mizuho lowers Glaukos stock price target to $130 on mixed outlook - Investing.com Nigeria
UBS Raises Price Target for Glaukos (GKOS) to $134, Keeps Buy Ra - GuruFocus
A Quick Look at Today's Ratings for Glaukos(GKOS.US), With a Forecast Between $115 to $130 - 富途牛牛
BTIG Adjusts Price Target for Glaukos (GKOS) Amid Sales Performance - GuruFocus
Glaukos (GKOS) Price Target Cut by Mizuho Amid Portfolio Concerns - GuruFocus
Glaukos price target lowered to $130 from $150 at Mizuho - TipRanks
Glaukos Corp's Q2 2025: Unraveling Key Contradictions in iDose Reimbursement, Reimplantation Timelines, and Growth Expectations - AInvest
Glaukos Corporation's 2025 Q2 Earnings: A Breakout Moment for MIGS and Dropless Innovation - AInvest
Glaukos Q2 2025 Earnings Call Transcript - MarketBeat
Glaukos Corporation Reports Strong Q2 2025 Growth - TipRanks
Glaukos Corp (GKOS): A High-Growth Play in Interventional Glaucoma Amid Regulatory and Market Headwinds - AInvest
Glaukos Corporation Revenue Projections and Strategic Insights - AInvest
Glaukos Announces Second Quarter 2025 Financial Results - BioSpace
Glaukos Corporation shares fall 2.49% after-hours after reporting a Q2 loss of $19.7 million. - AInvest
Earnings call transcript: Glaukos Corp beats Q2 2025 earnings estimates, stock dips - Investing.com
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Glaukos shares fall as revenue beat overshadowed by guidance concerns - Investing.com Nigeria
Glaukos Reports Record Q2 Sales, Raises 2025 Guidance - TipRanks
Glaukos Corp earnings beat by $0.02, revenue topped estimates - Investing.com Nigeria
Glaukos Corporation Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.74%
0.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):